Delivery Order SPE2DR25D9354-SPE2DR26FQLP7

The Defense Logistics Agency awarded a $10,230 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Prolastin C 1,000 mg/20 ml vials. The delivery order, issued on January 27, 2026, with an ultimate completion date of February 18, 2026, was awarded without a set-aside designation, reflecting the contractor's competitive capability in unrestricted federal procurement. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $499.999 billion contract awarded in November 2025 that positions the company as a critical regional pharmaceutical supplier for Department of Defense medical operations.

DMS Pharmaceutical Group has demonstrated substantial federal contracting activity as a prime vendor under the PPV-G GEN V framework, which is part of the broader $30.3 billion Defense Logistics Agency acquisition strategy to ensure consistent pharmaceutical supply to military healthcare facilities worldwide. The company supplies a comprehensive range of pharmaceutical products including branded and generic medications, biologics, vaccines, and specialty pharmaceuticals to support recurring medical supply needs across the Department of Defense. With no identified subcontractors and consistent performance on multiple delivery orders ranging significantly in value, DMS Pharmaceutical Group serves as an essential pharmaceutical supplier within the federal military medical supply chain.